In short
In recent clinical trials, researchers are investigating the potential of Mva-209-Fsp-B4, a component of the Nous-209 genetic vaccine, for treating advanced microsatellite instability-high (MSI-H) colorectal cancer. This innovative approach combines genetic vaccination with immunotherapy, aiming to provide new hope for patients with this challenging form of cancer. The trials are designed to assess the safety, efficacy, and anti-tumor activity of this treatment strategy in various patient populations.
At a glance
- Drug Name
- Mva-209-Fsp-B4 (part of Nous-209 genetic vaccine)
- Trial Phase
- Phase I/II
- Target Condition
- Advanced MSI-H or dMMR Colorectal Cancer
- Administration
- Intramuscular injection
- Combination Therapy
- Used with pembrolizumab (immunotherapy)
- Primary Objectives
- Assess safety, tolerability, and anti-tumor activity
- Key Outcomes Measured
- Overall Response Rate (ORR), Duration of Response (DoR), Progression-Free Survival (PFS)
- Eligibility
- Adults (18+) with MSI-H/dMMR CRC, meeting specific health criteria
What is MVA-209-FSP?
MVA-209-FSP is an experimental genetic vaccine being studied for the treatment of certain types of cancer. It is part of a class of treatments called immunotherapies, which work by helping your body's immune system fight cancer. The full name of this treatment is "Modified Vaccinia Ankara (MVA) 209 Frame Shift Peptide vaccine."
How does it work?
MVA-209-FSP is composed of four different vectors (carriers) named MVA-209-FSP-B1, MVA-209-FSP-B2, MVA-209-FSP-B3, and MVA-209-FSP-B4. Each of these carriers contains genetic instructions for making 209 special proteins called Frame Shift Peptides (FSPs). These FSPs are abnormal proteins that are often found in certain types of cancer cells but not in normal cells. By introducing these FSPs into the body, the vaccine aims to "train" the immune system to recognize and attack cancer cells that produce these abnormal proteins.
What conditions does it target?
MVA-209-FSP is being studied for the treatment of microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer that is locally advanced, unresectable (cannot be removed by surgery), or has spread to other parts of the body (metastatic). These terms describe specific genetic characteristics of the cancer that make it potentially responsive to this type of treatment.
Current Clinical Trial
MVA-209-FSP is currently being tested in a Phase I/II clinical trial. This means it's still in the early stages of research. The study is designed to: Determine if the treatment is safe See how well it works in fighting cancer Find the right dose to use Understand how it interacts with other cancer treatments, particularly a drug called pembrolizumab (another type of immunotherapy)
How is it administered?
MVA-209-FSP is given as an intramuscular injection, which means it's injected directly into a muscle. The exact schedule of when and how often it's given will depend on the specific phase of the clinical trial.
Who is eligible for the treatment?
The current clinical trial has specific eligibility criteria. In general, patients must: Be 18 years or older Have confirmed MSI-H or dMMR colorectal cancer Have cancer that is advanced or has spread Be in relatively good overall health Not have certain other medical conditions or be taking certain medications that might interfere with the treatment It's important to note that eligibility can vary depending on which part of the trial a patient might enter.
Potential Benefits
While it's too early to know for certain how effective MVA-209-FSP will be, the hope is that it will help the immune system fight cancer more effectively. The researchers are looking at several ways to measure its effectiveness, including: Whether tumors shrink or disappear (called "response rate") How long any improvements last How long patients live without their cancer getting worse These potential benefits are still being studied and are not guaranteed.
Safety Considerations
As with any experimental treatment, there may be risks and side effects that are not yet fully known. The clinical trial is designed to carefully monitor patients for any adverse effects. Some general considerations include: Patients should not receive certain live vaccines while on this treatment The treatment may affect the immune system, so patients with certain immune-related conditions may not be eligible Pregnant or breastfeeding women are not eligible for the current trial Always discuss potential risks and benefits with a healthcare provider.